23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › INTRA-CELLULAR THERAPIES INC. › 2023-2024

INTRA-CELLULAR THERAPIES INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed June 18, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 363Asset managers, any item
  • 2,071Fund votes
  • June 14, 2024Meeting date

Results at a glance

Meeting of June 14, 2024: 4 items on INTRA-CELLULAR THERAPIES INC.’s Form 8-K, filed June 18, 2024: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 1 director (41.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore INTRA-CELLULAR THERAPIES INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by INTRA-CELLULAR THERAPIES INC.

These tallies are INTRA-CELLULAR THERAPIES INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

INTRA-CELLULAR THERAPIES INC. — official shareholder meeting results, meeting held June 14, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Joel S. Marcus 54,287,176---- 38,126,4123,812,995 59%Passed (calculated)—
2. Approval of the Amended 2018 Plan, based on the following results 85,384,8802,956,9624,071,746 --3,812,995 97%Passed (calculated)—
3. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 88,688,9883,237,8074,299,788 --0 96%Approved—
4. On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement 80,788,1257,537,8684,087,595 --3,812,995 91%Approved—

Source: INTRA-CELLULAR THERAPIES INC., Form 8-K, filed with the SEC on June 18, 2024 — read the filing on EDGAR.

How asset managers voted at the INTRA-CELLULAR THERAPIES INC. 2023-2024 meeting

363 asset managers disclosed a vote on at least one INTRA-CELLULAR THERAPIES INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Joel S. Marcus

Calculated outcomeFund totals may overlapDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

59% Majority: yes · of votes cast

FOR 59%WITHHELD
FOR: 54,287,176WITHHELD: 38,126,412
Details: description as filed, official tally, votes by 113 asset managers

Description as filed by funds: To elect one director to serve a three-year term expiring in 2027: Joel S. Marcus

INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“Elect Director: Joel S. Marcus”): 54,287,176 for, 38,126,412 withheld, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 59% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 110 asset managers voting on “To elect one director to serve a three-year term expiring in 2027: Joel S. Marcus” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard958,5500 09,534,538Mixed
Fidelity10,125,0190 061,058For
BlackRock00 04,545,940Withhold
WASATCH FUNDS TRUST2,135,7260 00For
Invesco00 02,049,627Withhold
T. Rowe Price1,258,6480 00For
Charles Schwab00 01,099,670Withhold
Legg Mason1,006,7170 00For
Delaware/Macquarie00 0990,389Withhold
JPMorgan892,7940 00For
TIAA00 0825,243Withhold
FRANKLIN STRATEGIC SERIES694,6090 00For
First Trust639,7660 00For
AllianceBernstein00 0570,007Withhold
Lord Abbett463,7620 00For
Columbia Threadneedle00 0419,947Withhold
Principal179,4280 0228,516Mixed
American Century390,4140 00For
Equitable1,2000 0357,520Withhold
Brighthouse107,6460 0234,892Mixed
Hartford307,7290 00For
AB DISCOVERY GROWTH FUND, INC.00 0267,081Withhold
Jackson National62,3340 0200,406Mixed
AMG FUNDS253,0680 00For
GENERAL AMERICAN INVESTORS CO INC244,0360 00For

Fund voting reports, all 110 managers: 22,165,607 for, 23,170,012 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To elect one director to serve a three-year term expiring in 2027: Joel S. Marcus” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC343,6060 00For
Altium Capital Management LP193,0000 00For
Erste Asset Management GmbH23,4000 00For

Institutional-manager reports, all 3 managers: 560,006 for.

Approval of the Amended 2018 Plan, based on the following results

Calculated outcomeFund totals may overlapCOMPENSATIONPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 85,384,880AGAINST: 2,956,962
Details: description as filed, official tally, votes by 113 asset managers

Description as filed by funds: To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.

INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“2. Approval of the Amended 2018 Plan, based on the following results”): 85,384,880 for, 2,956,962 against, per its Form 8-K filed June 18, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of INTRA-CELLULAR THERAPIES INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 109 asset managers voting on “To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,493,0880 00For
Fidelity10,186,0770 00For
BlackRock4,545,9400 00For
WASATCH FUNDS TRUST2,135,7260 00For
Invesco2,049,6270 00For
T. Rowe Price1,258,6480 00For
Charles Schwab1,099,6700 00For
Legg Mason1,006,7170 00For
Delaware/Macquarie990,3890 00For
JPMorgan892,7940 00For
TIAA825,2430 00For
FRANKLIN STRATEGIC SERIES694,6090 00For
First Trust639,7660 00For
AllianceBernstein570,0070 00For
Lord Abbett463,7620 00For
Columbia Threadneedle419,9470 00For
Principal300,618107,326 00Mixed
American Century0390,414 00Against
Equitable358,7200 00For
Brighthouse342,5380 00For
Hartford307,7290 00For
AB DISCOVERY GROWTH FUND, INC.267,0810 00For
Jackson National262,7400 00For
AMG FUNDS253,0680 00For
GENERAL AMERICAN INVESTORS CO INC244,0360 00For

Fund voting reports, all 109 managers: 44,552,288 for, 746,292 against, 1 withheld, 17,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To approve the amendment and restatement of the Company's Amended and Restated 2018 Equity Incentive Plan.” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC343,6060 00For
Altium Capital Management LP193,0000 00For
MITCHELL CAPITAL MANAGEMENT CO3000 00For

Institutional-manager reports, all 3 managers: 536,906 for.

On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

91% Approved · of votes cast

FOR 91%
FOR: 80,788,125AGAINST: 7,537,868

Prior year: 93.1% for (June 23, 2023 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 360 asset managers

Description as filed by funds: To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the proxy statement.

INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“4. On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement”): 80,788,125 for, 7,537,868 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “On an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement was approved, based on the following votes:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 110 asset managers voting on “To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,493,0880 00For
Fidelity10,186,0770 00For
BlackRock4,545,9400 00For
WASATCH FUNDS TRUST2,135,7260 00For
Invesco02,049,627 00Against
T. Rowe Price1,258,6480 00For
Charles Schwab1,099,6700 00For
Legg Mason1,006,7170 00For
Delaware/Macquarie990,3890 00For
JPMorgan892,7940 00For
TIAA825,2430 00For
FRANKLIN STRATEGIC SERIES694,6090 00For
First Trust639,7660 00For
AllianceBernstein570,0070 00For
Lord Abbett463,7620 00For
Columbia Threadneedle419,9470 00For
Principal407,9440 00For
American Century0390,414 00Against
Equitable358,7200 00For
Brighthouse107,646234,892 00Mixed
Hartford273,38234,347 00Mixed
AB DISCOVERY GROWTH FUND, INC.267,0810 00For
Jackson National0262,740 00Against
AMG FUNDS253,0680 00For
GENERAL AMERICAN INVESTORS CO INC244,0360 00For

Fund voting reports, all 110 managers: 42,089,931 for, 3,228,151 against, 1 withheld, 17,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 278 asset managers voting on “To approve by an advisory vote the compensation of the Company's named executive officers, as disclosed in the” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Fidelity12,629,6100 00For
BlackRock3,418,21119,868 00For
WASATCH ADVISORS LP2,780,28120,192 00For
GEODE CAPITAL MANAGEMENT, LLC2,204,6350 00For
State Street1,996,11528,267 00For
Invesco02,015,113 00Against
Clearbridge Investments, LLC1,687,918161 00For
T. Rowe Price1,651,0720 00For
Deep Track Capital, LP1,525,9910 00For
JPMorgan1,500,1180 00For
AllianceBernstein1,465,0420 00For
Wellington1,423,2090 00For
FRANKLIN ADVISERS INC1,372,1140 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST1,291,5510 00For
SUVRETTA CAPITAL MANAGEMENT, LLC1,280,7680 00For
GW&K Investment Management, LLC1,206,6143,989 00For
Charles Schwab1,122,6100 00For
Avoro Capital Advisors LLC1,072,1730 00For
PICTET ASSET MANAGEMENT SA1,051,5070 00For
PERCEPTIVE ADVISORS LLC924,5900 00For
Northern Trust840,6345,131 00For
Nuveen829,7320 00For
SCHRODER INVESTMENT MANAGEMENT GROUP0625,114 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.625,0000 00For
LORD, ABBETT & CO. LLC523,2180 00For

Institutional-manager reports, all 278 managers: 54,694,995 for, 5,764,498 against, 62 not voted, 2 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 88,688,988AGAINST: 3,237,807
Details: description as filed, official tally, votes by 115 asset managers

Description as filed by funds: To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

INTRA-CELLULAR THERAPIES INC.’s own tally for this item (“3. Appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 88,688,988 for, 3,237,807 against — passed, per its Form 8-K filed June 18, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified, based on the following results:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 111 asset managers voting on “To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting fi” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,493,0880 00For
Fidelity10,186,0770 00For
BlackRock4,545,9400 00For
WASATCH FUNDS TRUST2,135,7260 00For
Invesco2,049,6270 00For
T. Rowe Price1,258,6480 00For
Charles Schwab1,099,6700 00For
Legg Mason1,006,7170 00For
Delaware/Macquarie990,3890 00For
JPMorgan892,7940 00For
TIAA825,2430 00For
FRANKLIN STRATEGIC SERIES694,6090 00For
First Trust639,7660 00For
AllianceBernstein570,0070 00For
Lord Abbett463,7620 00For
Columbia Threadneedle419,9470 00For
Principal407,9440 00For
American Century390,4140 00For
Equitable358,7200 00For
Brighthouse342,5380 00For
Hartford307,7290 00For
AB DISCOVERY GROWTH FUND, INC.267,0810 00For
Jackson National262,7400 00For
AMG FUNDS253,0680 00For
GENERAL AMERICAN INVESTORS CO INC244,0360 00For

Fund voting reports, all 111 managers: 45,215,652 for, 102,680 against, 1 withheld, 17,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 4 asset managers voting on “To ratify of the appointment of Ernst & Young LLP as the Company's independent registered public accounting fi” at INTRA-CELLULAR THERAPIES INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
TimesSquare Capital Management, LLC343,6060 00For
Altium Capital Management LP193,0000 00For
Erste Asset Management GmbH23,4000 00For
ZIMMERMANN INVESTMENT MANAGEMENT & PLANNING LLC830 00For

Institutional-manager reports, all 4 managers: 560,089 for.

Largest INTRA-CELLULAR THERAPIES INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported.

Fund voting reports: top INTRA-CELLULAR THERAPIES INC. shareholders by shares voted on “To ratify of the appointment of Ernst & Young LLP as the Company's independent registered…”, 2023-2024
#Asset manager Shares voted
1Vanguard 10,493,088
2Fidelity 10,186,077
3BlackRock 4,545,940
4WASATCH FUNDS TRUST 2,135,726
5Invesco 2,049,627
6T. Rowe Price 1,258,648
7Charles Schwab 1,099,670
8Legg Mason 1,006,717
9Delaware/Macquarie 990,389
10JPMorgan 892,794
Institutional-manager reports: top INTRA-CELLULAR THERAPIES INC. shareholders by shares voted on “To approve by an advisory vote the compensation of the Company's named executive officers, as…”, 2023-2024
#Asset manager Shares voted
1Fidelity 12,629,610
2BlackRock 3,438,079
3WASATCH ADVISORS LP 2,800,473
4GEODE CAPITAL MANAGEMENT, LLC 2,204,635
5State Street 2,024,382
6Invesco 2,015,113
7Clearbridge Investments, LLC 1,688,079
8T. Rowe Price 1,651,072
9Deep Track Capital, LP 1,525,991
10JPMorgan 1,500,118

Shown as share counts, not percentages: no shares-outstanding figure has been matched to INTRA-CELLULAR THERAPIES INC. for the 2023-2024 season, so there is no denominator to divide by.

About this meeting

At INTRA-CELLULAR THERAPIES INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 363 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 2,071 separate fund positions. On the most widely held item on that ballot — To approve by an advisory vote the compensation of the Company's named executive officers, as… — INTRA-CELLULAR THERAPIES INC.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: INTRA-CELLULAR THERAPIES INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

INTRA-CELLULAR THERAPIES INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Cite this page

Proxy Votes Now, “INTRA-CELLULAR THERAPIES INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/intra-cellular-therapies-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.